DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

Ten stocks led a lackluster performance on Monday, defying a broader market optimism, amid a series of company-specific news that included dismal earnings and a lower growth outlook, among others.